Gilead

Several biotech stocks were on the move Monday after Deutsche Bank started rating them. The bank's analyst, Robyn Karnauskas, took a generally wary view on the biotech sector, putting buy ratings only on Gilead and Dendreon.

Just because a drug has managed to successfully meet earlier trial goals, it's no guarantee it will continue to do so. On Tuesday, Gilead, Elan and Transition Therapeutics halted trials of experimental drugs that had previously showed promising results. Elan Corp. (ELN) and Transition Therapeutics...

Biotechnology company United Therapeutics Corp. (UTHR) announced today it has received a Food and Drug Administration approval for Adcirca, once-a-day 40 mg tablets for the treatment of pulmonary arterial hypertension (PAH). PAH is a progressive, life-threatening disease in which the pressure in a...